Dylan Glubb

Large numbers of germline genetic variants have been found to associate with disease. A major roadblock in our understanding of how genetics contribute to disease has been a lack of knowledge of the molecular effects of variants. Thus, the aim of my research program is to use genetic analyses to assign function and gene targets to variants associated with disease-related phenotypes. Dylan's knowledge impact is evidenced by 19 articles, with an average of 27 citations per article and 12 articles in journals in top 10% of their field (e.g. Nature, Nat Genet, Am J Hum Genet). Key impacts include:

•Identifying >30 genes with evidence of targeting by disease-related variants (18 articles)

•Providing support for the new paradigm that multiple variants affect target gene expression at disease loci (Corradin et al. Nat Genet 2016)

•Calibrating a functional assay for diagnostic assessment of Lynch syndrome genetic variants of uncertain significance (Drost et al, Genet Med 2018; in top 2% of articles for online attention)

As evidence of significant influence beyond my field, Dylan’s research has:

•Led (in collaboration with Dr McHugh, University of Huddersfield) to screening of ~400,000 compounds by the European Lead Factory (EU public-private partnership; project #ELFSC13_03), identifying candidates that target ADM receptors for pain/depression therapy

•Been cited in 53 research areas (Web of Science)

As evidence of recognition of Dylan's research program across multiple countries/beneficiaries:

•His articles have been cited by researchers from 1912 institutions from 41 countries (Web of Science) and been downloaded 8,510 times (ScienceDirect)

•6 articles have been mentioned in 72 news stories in 11 countries, 7 have online attention scores in the top 10% (Altmetric)

•Dylan has spoken at 8 international meetings and received 6 international awards, including selection as one of 12 finalists (550 applicants) for the ASHG/Charles J. Epstein Award for Excellence in Human Genetics Research